News
![](https://www.vivebiotech.com/wp-content/uploads/2023/07/Foto-scaled.jpg'))
16 December 2022
VIVEbiotech collaborates in the 4th edition of the ADEGI´s INDUSTRIA EGUNA
VIVEbiotech has participated in the 4th edition of the INDUSTRIA EGUNA organised by ADEGI - Business Association of Gipuzkoa.
Read more![](https://www.vivebiotech.com/wp-content/uploads/2022/12/International-meetings-2022.jpg'))
15 November 2022
Successful participation of VIVEbiotech in international events in 2022
VIVEbiotech has successfully participated in 7 international events during 2023.
Read more![](https://www.vivebiotech.com/wp-content/uploads/2023/07/Webinar.jpg'))
11 November 2022
VIVEbiotech presents its highly flexible and customized approach to lentiviral vector manufacturing at BioProcess International
VIVEbiotech has presented a webinar entitled “Flexible and Customized Approach to Lentiviral Vector Development and Manufacture Through a Well-Established Platform” last Tuesday, November 8.
Read more![](https://www.vivebiotech.com/wp-content/uploads/2023/07/Imagen-1.jpg'))
24 October 2022
VIVEbiotech participates in the 4th edition of New Culturers Gunea
VIVEbiotech has participated in the 4th edition of New Culturers Gunea that took place in FabrikaNCE last 19th October: a very interesting event to show...
Read more![](https://www.vivebiotech.com/wp-content/uploads/2023/07/Gurutz.jpg'))
21 October 2022
Gurutz Linazasoro, CEO of VIVEbiotech, participates in a conference organized by AseBio and CIBER
Gurutz Linazasoro, CEO of VIVEbiotech, has participated in the conference called "Terapias avanzadas (TA): de la academia a la industria" organized by AseBio, the Spanish...
Read more![](https://www.vivebiotech.com/wp-content/uploads/2023/07/Image.jpg'))
19 October 2022
VIVEbiotech presents its highly optimized transfection process in a webinar with Polyplus
VIVEbiotech has participated in a webinar entitled “The importance of raw materials to succeed in lentiviral vector manufacturing” together with Polyplus.
Read more![](https://www.vivebiotech.com/wp-content/uploads/2023/07/1665476020823.png'))
13 October 2022
VIVEbiotech´s scalable, regulatory compliant and cost-effective platform presentation together with Univercells Technologies
VIVEbiotech has participated in a webinar entitled “How to find success with lentiviral production using fixed bed bioreactor technology?” together with Univercells Technologies.
Read more21 September 2022
VIVEbiotech, one of the three only companies to obtain a PERTE
VIVEbiotech has obtained the PERTE called “Salud de Vanguardia/State-Of-The-Art Health” by the Ministry of Industry of the Spanish Government which is financed with European...
Read more![](https://www.vivebiotech.com/wp-content/uploads/2022/06/Image.jpg'))
21 June 2022
VIVEbiotech continues the expansion of its lentiviral vector manufacturing capabilities to address the viral vector bottleneck
VIVEbiotech, a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today announces its Good Manufacturing Practice (GMP)-accredited...
Read more![](https://www.vivebiotech.com/wp-content/uploads/2022/05/2022_05_04-Medicine-Maker-Natalia.jpg'))
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
Read more